Calidi Biotherapeutics Statistics
Want to see CLDI full AI Analyst Report?
Calidi Biotherapeutics (CLDI) Stock Statistics & Valuation Metrics
Total Valuation
Calidi Biotherapeutics has a market cap or net worth of $2.29M. The enterprise value is -$492.68K.
- Market Cap
- $2.29M
- Enterprise Value
- -$492.68K
Share Statistics
Calidi Biotherapeutics has 3,676,474 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,676,474
- Owned by Insiders
- 9.92%
- Owned by Institutions
- 1.00%
Financial Efficiency
Calidi Biotherapeutics’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -314.38%.
- Return on Equity (ROE)
- -5.30
- Return on Assets (ROA)
- -2.25
- Return on Invested Capital (ROIC)
- -314.38%
- Return on Capital Employed (ROCE)
- -4.11
- Revenue Per Employee
- 0
- Profits Per Employee
- -686.41K
- Employee Count
- 29
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Calidi Biotherapeutics is -0.03. Calidi Biotherapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.03
- PS Ratio
- 0.00
- PB Ratio
- 0.91
- Price to FCF
- -0.14
- Price to Operating Cash Flow
- -0.09
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Calidi Biotherapeutics had revenue of 0 and earned -19.91M in profits. Earnings per share was -95.20.
- Revenue
- 0
- Gross Profit
- -1.65M
- Operating Income
- -20.24M
- Pretax Income
- -20.05M
- Net Income
- -19.91M
- EBITDA
- -18.19M
- Earnings Per Share (EPS)
- -95.20
Cash Flow
In the last 12 months, operating cash flow was -15.85M and capital expenditures -53,000, giving a free cash flow of -15.90M billion.
- Operating Cash Flow
- -15.85M
- Free Cash Flow
- -15.90M
- Free Cash Flow per Share
- -6.42
Dividends & Yields
Calidi Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -720.98%
- Earnings Yield
- -1074.99%
Stock Price Statistics
- Beta
- 1.01
- 52-Week Price Change
- -97.49%
- 50-Day Moving Average
- 0.94
- 200-Day Moving Average
- 3.33
- Relative Strength Index (RSI)
- 31.92
- Average Volume (3m)
- 108.65K
Important Dates
Calidi Biotherapeutics upcoming earnings date is Mar 12, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Mar 12, 2027
- Ex-Dividend Date
- ―
Financial Position
Calidi Biotherapeutics as a current ratio of 1.59, with Debt / Equity ratio of 68.21%
- Current Ratio
- 1.59
- Quick Ratio
- 1.59
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- 0.17
- Interest Coverage Ratio
- -97.78
Taxes
In the past 12 months, Calidi Biotherapeutics has paid 15.00K in taxes.
- Income Tax
- 15.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Calidi Biotherapeutics EV to EBITDA ratio is 0.05, with an EV/FCF ratio of 0.05.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.05
- EV to Free Cash Flow
- 0.05
- EV to Operating Cash Flow
- 0.05
Balance Sheet
Calidi Biotherapeutics has $3.95M in cash and marketable securities with $1.02M in debt, giving a net cash position of $2.92M billion.
- Cash & Marketable Securities
- $3.95M
- Total Debt
- $1.02M
- Net Cash
- $2.92M
- Net Cash Per Share
- $0.80
- Tangible Book Value Per Share
- $0.66
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Calidi Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 85.56%
Scores
- Smart Score
- ―
- AI Score
- 41

